Overview
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.
Eligibility
Key Inclusion Criteria:
- Participants must have serologically confirmed Graves' Disease.
Key Exclusion Criteria:
- History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within six weeks of the Baseline visit.
- History of treatment with radioactive iodine or thyroid surgery.